DOI 10.3390/diagnostics16162612
Analytical Comparison of an In-House FARR Fluorescence Immunoassay with Commercial Analytical Assays for the Detection of Anti-Double-Stranded DNA Antibodies.
Аннотация
Background/
Objectives
Anti-double-stranded DNA antibodies (anti-dsDNA) are a specific biomarker for systemic lupus erythematosus (SLE). We aimed to analytically compare the in-house Farr fluorescence immunoassay (Farr-FIA), developed based on classical Farr-RIA, for the detection of anti-dsDNA with commercially available assays, including a chemiluminescence assay (CLIA) and the Crithidia luciliae immunofluorescence test (CLIFT). Additionally, we evaluated analytical agreement for diagnostic combinations of these methods.
Methods
We analyzed 182 samples from patients at the Department of Rheumatology, UMC Ljubljana, using Farr-FIA, CLIFT (Immuno Concepts-CLIFT 1 and Inova Diagnostics-CLIFT 2), and the QUANTA Flash dsDNA CLIA on the BIO-FLASH analyzer (Inova Diagnostics). Agreement between methods and diagnostic combinations was assessed using Cohen's kappa.
Results
Overall agreement between methods using manufacturer determined cut-offs ranged from 78.6% to 91.8% (κ = 0.582-0.836). The in-house Farr-FIA showed 78.6-86.8% comparability with commercial assays (κ = 0.582-0.730). Analytical agreement between combinations of two methods ranged from κ = 0.788 to 1.000, indicating moderate to almost perfect agreement. Our routine combination of CLIFT 1 followed by Farr-FIA showed high agreement (κ = 0.788-0.938) with other two-step approaches. Regardless of initial screening (CLIFT 1, CLIFT 2, or CLIA), applying Farr-FIA as a confirmatory method yielded highly consistent final classifications (97.3-100% agreement). However, the screening methods differed in the proportion of samples requiring confirmatory method (e.g., CLIFT 2 identified more positives requiring Farr-FIA), consequently affecting workflow and costs, although the final diagnostic results remain the same.
Conclusions
Farr-FIA demonstrated moderate to substantial analytical agreement with established commercial assays (CLIA and CLIFT). Several diagnostic combinations demonstrated high analytical agreement; however, the choice of initial screening method substantially influences the number of samples requiring confirmatory testing and, therefore, affects laboratory workload.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.